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Abstract
Background: The standard of care for colorectal peritoneal carcinomatosis is evolving from chemotherapy to 
cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with disease limited 
to the peritoneum. Peritoneal carcinomatosis from colorectal cancer treated with chemotherapy alone results in 
median survival of 5 to 13 months, whereas CRS with HIPEC for early peritoneal carcinomatosis from colorectal cancer 
resulted in median survival of 48-63 months and 5 year survival of 51%.
Completeness of cytoreduction and limited disease are associated with longer survival, yet early peritoneal
carcinomatosis is undetectable by conventional imaging. Exploratory laparotomy can successfully identify early
disease, but this approach can only be justified in patients with high risk of peritoneal carcinomatosis. Historical data
indicates that patients presenting with synchronous peritoneal carcinomatosis, ovarian metastases, perforated primary
tumor, and emergency presentation with bleeding or obstructing lesions are at high risk of peritoneal carcinomatosis.
Approximately 55% of these patient populations will develop peritoneal carcinomatosis. We hypothesize that
performing a mandatory second look laparotomy with CRS and HIPEC for patients who are at high risk for developing
peritoneal carcinomatosis from colorectal cancer will lead to improved survival as compared to patients who receive
standard of care with routine surveillance.
Methods/Design: This study is a prospective randomized trial designed to answer the question whether mandatory 
second look surgery with CRS and HIPEC will prolong overall survival compared to the standard of care in patients who 
are at high risk for developing peritoneal carcinomatosis from colorectal cancer (CRC). Patients with CRC at high risk for 
developing peritoneal carcinomatosis who underwent curative surgery and subsequently received standard of care 
adjuvant chemotherapy will be evaluated. The patients who remain without evidence of disease by imaging, physical 
examination, and tumor markers for 12 months after the primary operation will be randomized to mandatory second 
look surgery or standard-of-care surveillance. At laparotomy, CRS and HIPEC will be performed with intraperitoneal 
oxaliplatin with concurrent systemic 5-fluorouracil and leucovorin. Up to 100 patients will be enrolled to allow for 35 
evaluable patients in each arm; accrual is expected to last 5 years.
Trial Registration: ClinicalTrials.gov ID: NCT01095523
Background
In the United States, approximately 108,070 patients are
diagnosed with colon cancer and 40,740 patients with
rectal cancer per year (colorectal cancer = CRC) [1].
49,970 patients die from CRC per year. Initially, perito-
neal carcinomatosis (PC) commonly occurs without sys-
temic dissemination. In one study of the 3019 patients
reviewed with CRC, 349 (13%) had carcinomatosis [2].
214 (61%) patients had synchronous disease and 135
(39%) patients had metachronous disease. 58% of syn-
chronous PC was limited to the peritoneal cavity and 64%
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of these patients had localized disease to one quadrant
[2]. Overall, recurrences are limited to the peritoneum in
25% of patients with CRC [3]. Approximately 8000
patients are diagnosed with synchronous PC in the
United States per year.
Modern chemotherapy has improved survival of
patients with PC, but despite increased response rates
and increased median survival, few patients experience
long term survival with chemotherapy alone. The median
survival of patients with PC without systemic dissemina-
tion was 7 months for the 3019 patients reported above
[2]. Another study prospectively evaluated 45 patients
with PC who achieved a median overall survival of 6
months [3]. 118 patients in a French registry showed a
median overall survival of 5.2 months [4]. Most of these
patients received systemic 5-FU and leucovorin-based
regimens. Although multiple reports of metastatic dis-
ease demonstrate an increased survival with current che-
motherapeutic regimens [5-10], Elias et al. reports the
only series that follows patients with PC without systemic
dissemination treated with current standard of care sys-
temic chemotherapy regimens of FOLFOX (5-fluoroura-
cil (5-FU), leucovorin, and oxaliplatin) and FOLFIRI (5-
fluorouracil (5-FU), leucovorin, and irinotecan). The
authors report a median survival of 23.9 months and 2-,
and 5-year survival of 65% and 13%, respectively [11].
Clearly, patients have benefited from better systemic reg-
imens, but at best, survival is only 13% at five years for
this group of patients treated with modern systemic che-
motherapy alone.
The prognosis of patients with PC has significantly
improved with the combination of cytoreductive surgery
(CRS) and hyperthermic intraperitoneal chemotherapy
(HIPEC) [11-13]. The 5-year overall survival ranges from
40 - 51%. The technique has previously been described as
peritonectomy, hyperthermia, and resection of intrab-
dominal disease as necessary [14-16]. Hyperthermia has
been shown to increase the cytotoxicity of chemotherapy
[17,18]. CRS and HIPEC initially began as the treatment
for appendiceal malignancy and malignant peritoneal
mesothelioma [19-21]. In 2006, this procedure was
declared the standard of care by the National Cancer
Institute for ovarian PC based on the results of a phase III
study [22]. In the past 8 years, two randomized clinical
trials (RCT), one nonrandomized comparative study, and
11 observational studies have been reported for colorec-
tal carcinomatosis and summarized in a comprehensive
review article by Yan et al [23].
Verwaal et al [24] performed a RCT of CRS and HIPEC
versus systemic chemotherapy alone which demonstrated
a significant survival benefit with increase in median sur-
vival of 22 mo. versus 12 mo. and 2-year survival of 44%
versus 22%, respectively. Even though this trial demon-
strates a clear benefit, the systemic therapy with 5-FU
and leucovorin is an outdated regimen compared to cur-
rent treatment of FOLFOX or FOLFIRI. In addition, the
HIPEC drug was mitomycin-C which is not the most
effective drug against CRC. Regardless, the patients who
underwent intent-to-treat randomization and received
CRS and HIPEC achieved a significant survival advantage
(p = 0.032). For the patients who received an R0 resec-
tion, the 2-year survival was 60%. A multi-institutional
registry [25] of 506 patients who underwent CRS and
HIPEC for CRC with PC demonstrated a 1-, 3-, and 5-
year survival of 72%, 39%, and 19%, respectively with a
median survival of 19 months. Again, similar to the RCT
data, patients with complete CRS achieved the highest
survival. The patients who underwent R0 resection
achieved a 1-, 3-, and 5-year survival of 87%, 47%, and
31%. The ten single institutional case-series reviewed by
Yan et al. [23] demonstrated overall median survivals
from 13 to 29 months and 1-, 2-, 3-and 5-year survival
rates of 55-75%, 31-64%, 21-28%, and 11-19%, respec-
tively. Clearly, with one trial of level 1 data, another with
good level 2 data, and multiple case series reporting
excellent survivals, CRS with HIPEC shows promise to
become the standard of care for CRC with PC.
Unfortunately, PC is usually detected late in the course
o f  d i s ease  s ec o n da ry  t o  la t e  p r es e n t a t i o n  o f  sym p t o m s
and difficulty with detection based upon imaging tech-
niques and tumor markers. Once symptomatic disease
develops, complete resection is more difficult to achieve.
The only reliable means of detection is repeat laparo-
tomy, but this operation cannot be justified in all patients
with CRC. High risk group of patients who may benefit
[26-28] have been defined after a prospective phase II
trial as those patients with synchronous limited PC at ini-
tial operation, synchronous ovarian metastases, perfo-
rated primary tumors, T4 lesions that required adjacent
organ resection, and emergency presentation for
obstructing and bleeding lesions [26]. 62% of patients
w i t h  l i m i t e d  P C  a t  p r e s e n t a t i o n ,  7 5 %  o f  p a t i e n t s  w i t h
ovarian metastases, 15% of patients with perforated CRC,
and 19% of patients with T4 lesions that required resec-
tion of adjacent organs will develop PC [2].
Given the impact on survival with CRS and HIPEC,
Elias et al. [26] performed a prospective study to analyze
the outcomes with mandatory second-look surgery
(MSLS) for patients at high-risk for recurrence as stated
above. All patients were NED based upon symptoms,
tumor markers, CT, and PET. Every patient had appropri-
ate primary resection with adjuvant FOLFOX or FOL-
FIRI as the current standard of care. Six months after the
last chemotherapy, MSLS was performed. Macroscopic
PC was found in 55% of the patients (16/29) who were
asymptomatic with negative evaluation. All of the
patients with recurrence were treated with CRS and
HIPEC. No post-operative mortality occurred. With aRipley et al. Trials 2010, 11:62
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median follow-up of 27 months, of the 16 patients with
recurrent peritoneal carcinomatosis, 8 (50%) remained
NED, 4 (25%) relapsed with PC (2 with distant metasta-
ses), and 4 (25%) developed visceral metastases. Most
importantly, this study revealed that high-risk patients
with recurrent PC are often detected only at laparotomy
despite appropriate surveillance and that the early detec-
tion of disease may result in complete CRS compared to
CRS of symptomatic disease or disease detected by imag-
ing.
Chemotherapeutic drugs used for intra-operative man-
agement are based on the most effective systemic regi-
mens which also demonstrate good results regarding
intraperitoneal delivery. Systemic oxaliplatin has demon-
strated significant activity against metastatic CRC with
an objective response rate of 24% as a single agent and
55% in combination with 5-FU and leucovorin (FOLFOX)
[8,29,30]. FOLFOX is one of the first line standard of care
regimens for metastatic CRC. Oxaliplatin is currently the
most studied intraperitoneal drug [31-33] and it is also
potentiated by hyperthermia and it works at all stages of
cell division [17,34].
In summary, for approximately 50% of patients who
develop PC from CRC, a complete resection may be
potentially curative. Patients with high-risk primary CRC
have an incidence of PC greater than 50%, yet modern
imaging and tumor or serum markers fail to detect recur-
rence at an early stage. We hypothesize that MSLS with
CRS and HIPEC in patients who are at high risk for recur-
rent PC will lead to improved survival compared to stan-
dard surveillance. Therefore, a prospective randomized
trial has been designed to evaluate MSLS with CRS and
HIPEC versus treatment of PC once disease is detected,
during routine surveillance, by imaging or symptoms.
Methods
Ethical Approval
The Mandatory Second Look Surgery (MSLS) for high
Risk Colorectal Cancer trial was approved by the Institu-
tional Review Board (IRB) of the National Cancer Insti-
tute, National Institutes of Health, Bethesda, Maryland.
Design
This study is a randomized controlled trial. The trial
schema is illustrated in Figure 1. The study will be per-
formed at the Clinical Center of the NIH by the Surgery
Branch of the NCI in Bethesda, Maryland, USA. Patients
who have undergone curative surgical resection for the
primary CRC tumor, are at high risk for development of
PC, have completed at least 3 months of standard of care
systemic therapy, and show no evidence of disease may be
enrolled and randomized to receive either standard of
care surveillance (SC) or mandatory second-look surgery
(MSLS) followed by CRS and HIPEC. Randomization will
occur between 11 - 14 months after the primary opera-
tion to allow flexibility in enrollment and accrual without
effect on design.
Stratification and Randomization
R e gis t r a t i o n  o f  pa t i e n ts  o n t o  t h is  s t u d y  wi l l  t a k e  p la c e
within 24 hours of the patient signing the consent by fax-
ing a completed eligibility checklist to the Central Regis-
tration Office. This trial will consist of three stages: Lead-
in Stage includes the time period from 3 months to 14
months following resection. Patients who present for
evaluation prior to month 11 post resection will be
enrolled in this stage prior to randomization. Stage 1
includes MSLS with HIPEC and CRS and the recovery
period. Patients who are randomized to receive surgical
intervention will be entered on stage 1. Stage 2 is the fol-
low up period. Patients who are randomized to surveil-
lance will be directly entered on stage 2; patients who are
randomized to the MSLS arm will be entered on stage 2
upon recovery from the operative procedure. After 11-14
months following primary resection, the patients will be
stratified and randomized by the Central Registration
Office to undergo MSLS with HIPEC and CRS or stan-
dard-of-care surveillance (SC) without surgery. The Cen-
tral Registration Office will notify the study coordinator
of the results of randomization. Patients must be ran-
domized within 2 weeks of the baseline imaging studies.
Patients who are randomized to the MSLS arm must be
treated within 2 weeks of randomization.
Patients will be stratified according to two factors: 1:
Presenting with PC, which was completely resected, and/
or ovarian metastases (incidence of recurrent PC > 60%)
vs. presenting with tumor perforation, T4 lesions that
required adjacent organ resection, and/or emergency
presentation with bleeding or obstructing lesions (inci-
dence of recurrent PC < 40%), and 2: Receiving adjuvant
Figure 1 Trial schema.Ripley et al. Trials 2010, 11:62
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chemotherapy for less than 6 months vs. > 6 months. This
will generate 4 strata.
Statistics
The primary objective of the trial is to determine if there
is a difference in overall survival among patients who are
at high risk for CRC PC and are randomized to receive
either SC alone or MSLS with HIPEC and CRS when
indicated.
Based upon results in the literature, patients who would
be eligible to be randomized on this trial and who receive
SC alone would be expected to have an estimated 25% 5-
year survival from the date of randomization. The goal of
this study will be to determine if the use of a MSLS with
HIPEC and CRS will result in patients having survival
that is associated with an increase to 50% 5-year survival.
Following registration, patients who are eligible for ran-
domization will be randomized between SC and MSLS
with HIPEC and CRS and followed for survival. Patients
will be stratified for synchronous peritoneal carcinoma-
tosis and ovarian metastasis vs. perforated primary and
emergency with bleeding or obstruction, and prior che-
motherapy ≤ 6 months vs. >6 months. Kaplan-Meier
curves and a two-tailed log-rank test will be the primary
analysis methods. Assuming exponential survival curves,
the hazard rate for the systemic therapy is 0.0231, or
approximately a 2.3% probability of dying each month
when the 5-year survival probability is 25%. If we assume
that the MSLS arm will have an associated survival of 50%
at 5 years, this survival corresponds to a hazard rate of
0.0116, and the resulting hazard ratio for the comparison
of the two overall survival curves would be 1.991. Follow-
ing the principles of a phase 2.5 design, to compare these
curves and detect a difference with a 0.10 one-tailed log-
rank test, a total of 35 evaluable subjects per arm (70
total) will need to be randomized over a five year period,
followed for an additional two years from the date of
entry of the last patient, and observation of 38 total
deaths in order to have 80% power to compare the curves.
It is expected that 80% of registered patients will be eli-
gible for the randomization. Thus, in order to enroll 70
randomized patients, a total of up to 100 evaluable
patients may be enrolled. The patients who present prior
to 11 months will be enrolled in the lead-in stage in which
some patients may develop symptomatic or image-
detected disease. These patients will not be eligible for
randomization, but the number of randomized patients
relative to enrolled patients will be noted in order to
determine the denominator of patients who develop peri-
toneal recurrence within the first year of treatment. Reg-
istration will be permitted to continue until 70 patients
have been randomized, and thus it is possible that up to
5-10 additional patients beyond 70 may be randomized.
This will permit a very small increase in power. Patients
will be analyzed as randomized; only patients found to be
grossly inevaluable for any reason will not be included in
the final analysis once randomized.
Progression-free survival will also be evaluated using
Kaplan-Meier curves and a two-tailed log rank test, as a
secondary endpoint. In addition, a prognostic factor eval-
uation using Cox proportional hazards modeling will take
place after the study has concluded in order to identify if
there are factors which can be identified that are associ-
ated with overall or progression-free survival in patients
randomized to treatments on this trial; this analysis will
be interpreted as a secondary endpoint.
It is expected that 20 patients per year can be accrued
onto this trial, and thus accrual will be completed in
approximately 5 years. Allowing for a very small number
of inevaluable patients, the accrual ceiling will be set at
100 patients in order to permit 95 registrations and 70-75
randomized patients.
Data and Safety Monitoring
Careful evaluation to ascertain the toxicity and clinical
response will be performed. The principal investigator
will monitor the data and toxicities in order to identify
trends quarterly. The principal investigator will be
responsible for revising the protocol as needed to main-
tain safety. The NCI IRB will review submitted adverse
events monthly to evaluate trends and will require a fol-
low-up plan from the principal investigator whenever a
trend is identified.
The study will be monitored by the NCI/CCR Data
Safety and Monitoring Board (DSMB) on an annual basis
to evaluate the safety of the two arms. The serious
adverse events (typically grade 3 or greater toxicities) will
be reported according to type of toxicity, maximal grade
noted per patient, and for toxicities with at least a possi-
ble attribution to the therapy provided on that arm. Com-
parisons will be made between the two arms using
Cochran-Armitage tests for trend, or other appropriate
methods, to determine if there is increased toxicity asso-
ciated with either arm.
Beginning at the first annual DSMB meeting after 35
patients have been randomized, annual interim evalua-
tions will be performed to determine if there is sufficient
evidence to terminate accrual because of a better than
expected improvement in survival.
Inclusion and Exclusion Criteria
Inclusion Criteria
• Histologically confirmed colorectal adenocarci-
noma.
• Curative resection (NED at closure) for CRC which
was (1) perforated into the peritoneal cavity, (2) asso-
ciated with minimal PC which was completely excised
at the time of initial operation, (3) T4 lesion thatRipley et al. Trials 2010, 11:62
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required en bloc resection of additional organs, (4)
associated with ovarian metastases or (5) emergency
presentation with lesions associated with obstruction
and/or bleeding.
 Note: Patient who presented at the time of diag-
nosis with limited extra abdominal metastases
may be eligible if the lesions were completely
resected and the patient remains NED.
• Received at least 3 months of standard of care adju-
vant therapy and is disease free by conventional imag-
ing at time of registration and randomization.
 Note: The imaging will be reviewed by an expe-
rienced radiologist and a surgical attending prior
to enrollment.
• Greater than or equal to 18 years of age.
• Clinical performance status of ECOG ≤ 2.
• Stable serum CEA levels not indicating recurrence.
• No history of prior/other malignancies within the 2
years prior to enrollment with the exception of basal
cell carcinoma.
Exclusion Criteria
• Active systemic infections, coagulation disorders, or
other major medical illnesses precluding major sur-
gery.
• Prior experimental therapy with novel agents.
• Prior HIPEC.
• History of brain metastases.
• Childs B or C cirrhosis or with evidence of severe
portal hypertension by history, endoscopy, or radio-
logic studies or with evidence of moderate to severe
ascites.
• Weight less than 40 kg.
• History of congestive heart failure and/or an LVEF <
40%.
• Significant COPD or other chronic pulmonary
restrictive disease with PFT's indicating an FEV1 less
than 50% or a DLCO less than 40% predicted for age.
Intervention
Mandatory Second-Look Surgery (MSLS) Arm
All patients randomized to the MSLS arm will undergo
exploratory laparotomy at the Surgery Branch, NCI. The
overall goal for surgical therapy is to determine whether
clinically occult metastases exist and to render the patient
NED with negative margins if metastases are detected.
All previous dissection planes should be open as feasibly
and safely as possible which requires an exploratory lapa-
rotomy because most recurrences detected at sites of
prior operative therapy that often have adhesions pre-
venting laparoscopic evaluation of these areas. Determi-
nation of NED status will be based upon visual
inspection, frozen biopsy of any suspicious lesions, and
ultrasound of liver with biopsy as indicated. Peritoneal
washings will be performed in all patients. Sixteen16
peritoneal biopsies will be done - 4 from each quadrant.
Data from these investigations will be used at the final
analysis of the risks and benefits of this approach. Pre-
and post-operative peritoneal disease will be recorded
using the PCI and the Gilly's methodology [35,36]. If any
means above detect recurrent disease, all disease will be
resected if technically feasible and HIPEC will be per-
formed in all patients. Complete peritonectomy will be
performed only in cases where carcinomatosis is detected
and confirmed by a frozen biopsy. For patients with peri-
toneal disease peritonectomy and CRS includes the fol-
lowing: The right and left sub-diaphragmatic
peritoneum, the falciform ligament, lesser and greater
omentum, anterior, right and left abdominal wall down to
the paracolic gutters, and the pelvic peritoneum. The sur-
geon has the discretion to perform partial peritonectomy
for limited disease which may include one or more of the
resections described above. Intra-operative hepatic ultra-
sound will be performed when clinically indicated.
For the HIPEC procedure, two large bore catheters
(thoracostomy tubes) will be inserted through the
abdominal wall incision, one over the right lobe of the
liver and one in the pelvis. The abdominal skin will be
closed and the catheters connected to a perfusion circuit.
The perfusate passes from a reservoir through a roller
pump, heat exchanger, and then into the abdominal cav-
ity. Efflux from a second catheter is then recirculated
through the reservoir and pump. The perfusion flow rate
will be maintained at 2.0 L/min and a perfusate volume
will be maintained which moderately distends the
abdominal cavity correlating with intra abdominal pres-
sures of 5 to 15 mm Hg (2.0 L/m2). Stable perfusion
parameters are obtained and the peritoneal cavity is
warmed to a minimum of 41°C prior to starting the clock
for perfusion time and a maximum of 43°C. The perfu-
sion will be continued for 30-35 minutes. During the per-
fusion, constant physical manipulation of the abdomen
(shaking) will be maintained for the entire perfusion
period to assure even distribution of the perfusate. The
heater coil will be maintained at 46-48°C. Peritoneal tem-
perature will be measured continuously by four probes
placed immediately beneath the peritoneal surface on
either side of the abdomen and in the pelvis. The patient's
core temperature will be measured with an esophageal
probe (which correlates well with pulmonary artery tem-
peratures) and maintained at less than 41°C using a cool-
ing blanket and ice packs around the legs and head. At the
end of the perfusion, the abdomen will be re-opened and
the perfusate irrigated from the abdominal cavity. All
intraperitoneal drug dosages will be calculated on ideal
body weight. 5-FU (400 mg/m2) and leucovorin (20 mg/
m2) will be administered intravenously 15 minutes prior
to HIPEC to potentiate the activity of oxaliplatin (460Ripley et al. Trials 2010, 11:62
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mg/m2 diluted in 2.0 L/m2 of D5W via the perfusion cir-
cuit).
During the post-operative period, patients will receive
all standard of care supportive measures. For patients
who undergo HIPEC, these measure include when indi-
cated: Broad-spectrum antibiotics for neutropenic fever;
filgrastim for ANC less than 1000 mm3, and avoidance of
renal toxic drugs, maintenance of good renal perfusion,
and diuretics as necessary for renal dysfunction.
Standard of Care Surveillance (SC) Arm
Patients in both arms will undergo the same follow-up
surveillance as noted in the next section. Patients who
have peritoneal recurrences detected on the surveillance
arm will be offered exploration if clinically appropriate
with potential CRS and HIPEC pending intra-operative
assessment of extent of disease.
Post-randomization surveillance for both arms
Follow-up will commence from randomization and will
occur every 3 months for two years. After two years, fol-
low-up will be extended to every six months, and after an
additional three years, follow-up will be yearly. At any
stage between these follow-ups additional evaluations
will be conducted as clinically indicated. At each evalua-
tion patients will undergo: Physical examination; labora-
tory tests; tumor markers; CT scan of the chest, abdomen
and pelvis; PET as medically indicated. Patients on both
arms who develop intra/extra-abdominal metastases will
be offered standard of care surgery when indicated and/
or referred to their treating physician or Medical Oncol-
ogy Branch, NCI, for systemic therapy.
Informed Consent
All patients are thoroughly screened prior to initial con-
sultation at the NIH. During the initial consultation, the
patient, along with family members, is presented a forth-
right and detailed overview of the treatment option avail-
able to them at the NIH. The experimental nature of the
treatment, its theoretical advantages and disadvantages,
and an overview of the operative procedure and antici-
pated convalescence are presented. The fact that the
patient may undergo an operative procedure in order to
receive therapy without any assurance of benefit, the
aggressive nature of the treatment, and the possibility of
serious or potentially life-threatening complications are
presented. The Informed Consent document is given to
the patient and they are asked to review it, make notes
and follow-up with a phone call to the physician or nurse
investigator to have any additional questions answered
prior to considering treatment on protocol. The research
nurse, principal investigator, or designee is responsible
for obtaining consent from the patient upon admission.
The signed consent will be verified by the physician
responsible for the care of the patient. Patients can with-
draw or decide against treatment at any time without
obligation.
Endpoints and Follow-up of Study
Primary Objectives
• To compare the overall survival of patients at high
risk for developing PC from CRC who undergo MSLS
with HIPEC and CRS (if applicable) vs. similar
patients who receive standard of care surveillance.
Secondary Objectives
• To determine recurrence-free survival from the time
of randomization in both arms.
• To investigate selection criteria for patients who
might benefit from MSLS with HIPEC and CRC.
• To determine the percentage of patients who are
diagnosed with recurrent peritoneal disease (gross vs.
microscopic) at exploration.
• To determine the percentage of patients with recur-
rent disease at MSLS who are successfully debulked to
R0.
• To determine the rate of clinical detection of PC
during the pre-randomization period and thereby
determining the denominator for this cohort of
patients.
Discussion
Colorectal cancer is the 3rd most common malignancy in
the United States accounting for over 100,000 new cases
per year [1]. Peritoneal carcinomatosis accounts for about
13% of metastatic spread among patients who die from
this disease [2]. Despite significant advances in chemo-
therapy with regimens such as FOLFOX and FOLFIRI, at
best about 13% of patients with peritoneal carcinomatosis
achieve 5-year survival with chemotherapy alone [26].
CRS and HIPEC have shown impressive results with 5-
year survivals of about 50% for patients with disease lim-
ited to the peritoneum [11,13,23]. The patients who con-
sistently experience the best survivals undergo complete
resection of peritoneal disease (R0 resection). Unfortu-
nately, this disease is not detectable by imaging, symp-
toms, or tumor markers early in the disease, yet early
intervention is more likely to achieve complete resection
of the disease. Therefore, identification of a patient popu-
lation at high risk for PC may allow earlier interventionin
order to undergo surgery completely resect recurrent dis-
ease has been proposed to increase survival in this
patient population.
This trial tests the strategy of mandatory second-look
laparotomy for patients at high risk of recurrent perito-
neal carcinomatosis versus the current standard-of-care
of routine surveillance. The high risk patients previously
have been defined as having limited and resected perito-
neal disease at initial operation, ovarian metastases,
tumor perforation, T4 lesions with en bloc adjacent organRipley et al. Trials 2010, 11:62
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resection, and emergency presentation with bleeding and
obstruction. Given that this patient population has high
risk of peritoneal recurrence that translates into very
poor survival, a strategy as invasive as an mandatory
exploratory second-look surgery is justified to determine
its impact on survival, yet this proposal should be sub-
jected to rigorous scientific scrutiny prior to implementa-
tion outside of a clinical trial. If the primary objective of
increasing overall survival is met, this trial may change
the current management of patients at high risk for devel-
oping recurrent peritoneal carcinomatosis to one of
aggressive, early, surgical intervention with strong evi-
dence to show that patients will benefit from this strategy.
Hopefully, this treatment will significantly increase long-
term survival among patients with peritoneal carcinoma-
tosis.
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